AstraZeneca and VaxEquity partner to advance RNA therapeutics
VaxEquity will receive development, approval and sales-based milestone payments of up to $195m from AstraZeneca.
deal
Immunic signs agreement to in-license assets to treat viral infections
A combination of DHODH inhibitor, IMU-838 and N4-hydroxycytidine offered a decline in viral RNA to...
AbCellera and Everest enter deal to discover antibody therapies
Everest will make research, milestone and royalty payments to AbCellera for the products developed through...
Boehringer acquires Abexxa Biologics to develop new cancer treatments
Through the acquisition, Boehringer will now have access to Abexxa’s expertise in targeting cancer-specific proteins.
Grifols agrees to acquire Tiancheng Pharmaceutical for $1.3bn
According to the transaction, the equity and enterprise value of Biotest is assessed at $1.9bn...
Philip Morris International acquires Fertin Pharma for $820m
Leveraging Fertin Pharma’s expertise, PMI plans to offer a wide range of smoke-free products such as nicotine pouches.
US to procure 1.4 million doses of Regeneron’s antibody cocktail
Regeneron plans to supply doses of 1,200mg REGEN-COV by 31 January next year priced at $2,100 per dose.
Sanofi concludes acquisition of Translate Bio for $3.2bn
Sanofi expects the deal to be vital for its mRNA Center of Excellence to unravel mRNA vaccines’ potential.
AzurRx BioPharma to acquire First Wave Bio for $229m
AzurRx’s management team comprising CEO James Sapirstein will remain in the role to lead the merged company.
AbbVie and Regenxbio collaborate to develop retinal disease therapy
Regenxbio is eligible for $370m in upfront and potential payments of up to $1.38bn on meeting certain milestones.
UK terminates Covid-19 vaccine supply agreement with Valneva
Valneva denied the claims made by the UK Government that Valneva breached obligations outlined in the supply deal.
